Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
As the federal government ends pre-approved benefits during the early stages of the COVID-19 pandemic, low-income Americans could receive less food assistance or lose their eligibility altogether.
Read Full NewsUse of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.
The therapy also received orphan drug designation from the FDA.
Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease
HCPLive 5 Stories in Under 5: Week of 01/11
Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars
1.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
2.
Single-dose radiation before surgery can eradicate breast cancer
3.
No Solace From Drug Scarcities; Novel Guidelines Regarding Lymphedema; A "Good" Patient Is Forgotten.
4.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
5.
Regular physical activity before cancer diagnosis may lower progression and death risks
1.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
2.
The Importance of Having a Quick and Effective Heparin Antidote
3.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
4.
Refractory Iron Deficiency Anemia in a Young Adult: Diagnostic Challenges
5.
Oncology Partnerships: Driving Innovation Through Strategic Collaborations and Pharma Engagement USA
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge